In the last trading session, 2.49 million Capricor Therapeutics Inc (NASDAQ:CAPR) shares changed hands as the company’s beta touched 0.83. With the company’s per share price at $14.23 changed hands at $1.05 or 7.97% during last session, the market valuation stood at $650.42M. CAPR’s last price was a discount, traded about -64.44% off its 52-week high of $23.40. The share price had its 52-week low at $3.52, which suggests the last value was 75.26% up since then.
Analysts gave the Capricor Therapeutics Inc (CAPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CAPR as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Capricor Therapeutics Inc’s EPS for the current quarter is expected to be -0.39.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Instantly CAPR was in green as seen at the end of in last trading. With action 43.88%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 3.12%, with the 5-day performance at 43.88% in the green. However, in the 30-day time frame, Capricor Therapeutics Inc (NASDAQ:CAPR) is 106.53% up.
The consensus price target for the stock as assigned by Wall Street analysts is 15, meaning bulls need an upside of 5.13% from its current market value. According to analyst projections, CAPR’s forecast low is 10 with 21.5 as the target high. To hit the forecast high, the stock’s price needs a -51.09% plunge from its current level, while the stock would need to tank 29.73% for it to hit the projected low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
Year-over-year growth is forecast to reach 366.12% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 2.6M. 8 analysts are of the opinion that Capricor Therapeutics Inc’s revenue for the current quarter will be 44.55M. The company’s revenue for the corresponding quarters a year ago was 3.97M and 2.26M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -34.60%. The estimates for the next quarter sales put growth at 1,869.81%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.01%. The 2025 estimates are for Capricor Therapeutics Inc earnings to increase by 96.52%.
CAPR Dividends
Capricor Therapeutics Inc is expected to release its next quarterly earnings report in July.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.8645% or 1.55 million shares worth $7.39 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . With 1.19 shares estimated at $16.94 million under it, the former controlled 2.61% of total outstanding shares. On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF held about 2.17% of the shares, roughly 992.14 shares worth around $14.12 million.
